Introduction
============

"'Drunkenness is nothing but voluntary madness.\'---Seneca"

Alcohol use and overuse (alcoholism) havedeep historical and cultural roots, as well as important medical and societal consequences.^[@bib1]^ Whereas there is evidence for roles for both genes and environment in alcoholism, a comprehensive biological understanding of the disorder has been elusive so far, despite extensive work in the field. Most notably, there has been until recently insufficient translational integration across functional and genetic studies, and across human and animal model studies, resulting in missed opportunities for a comprehensive understanding.

As part of a translational Convergent Functional Genomics (CFG) approach, developed by us over the last 15 years,^[@bib2]^ and expanding upon our earlier work on identifying genes for alcoholism,^[@bib3],\ [@bib4],\ [@bib5]^ we set out to comprehensively identify candidate genes, pathways and mechanisms for alcoholism, integrating the available evidence in the field to date. We have used data from a published German genome-wide association study for alcoholism.^[@bib6]^ We integrated those data in a Bayesian-like manner with other human genetic data (association or linkage) for alcoholism, as well as human gene expression data, post-mortem brain gene expression data and peripheral (blood and cell culture) gene expression data. We also used relevant animal model genetic data (transgenic and quantitative trait loci (QTL)), as well as animal model gene expression data (brain and blood) generated by our group andothers ([Figures 1 and](#fig1){ref-type="fig"} [2](#fig2){ref-type="fig"}). Human data provide specificity for the illness, and animal model data provide sensitivity of detection. Together, they helped to identify and prioritize candidate genes for the illness using a polyevidence CFG score, resulting in essence in a *de facto* field-wide integration putting together all the available lines of evidence to date. Once that is done, biological pathway analyses can be conducted and mechanistic models can be constructed.

An obvious next step is developing a way of applying that knowledge to genetic testing of individuals to determine risk for the disorder. On the basis of our comprehensive identification of top candidate genes described in this paper, we have chosen all the nominally significant *P*-value SNPs corresponding to each of those 135 genes from the GWAS data set used for discovery (top candidate genes prioritized by CFG with the score of 8 and above (≥50% maximum possible CFG score of 16) and assembled a Genetic Risk Prediction panel out of those 713 SNPs. We then developed a Genetic Risk Prediction Score (GRPS) for alcoholism based on the presence or absence of the alleles of the SNPs associated with the illness from the discovery GWAS, and tested the GRPS in an independent German cohort,^[@bib51]^ to see whether it can differentiate alcohol-dependent subjects from controls, observing a trend towards significance.

In order to validate and prioritize genes in this panel using a behavioral prism, we then looked at the overlap between our panel of 135 top candidate genes and genes changed in expression in a stress-reactive animal model for alcoholism developed by our group, the DBP knockout mouse.^[@bib4],[@bib5]^ We used this overlap to reduce our panel to 11 genes (66 SNPs).

This small panel of 11 genes was subsequently  tested and shown to be able to differentiate between alcoholics and controls in the three independent test cohorts, one German^[@bib51]^ and two US-based,^[@bib52]^ suggesting that the animal model served in essence as a filter to identify from the larger list of CFG-prioritized genes the key behaviorally relevant genes. Our results indicate that panels of SNPs in top genes identified and prioritized by CFG analysis and by a behaviorally relevant animal model can differentiate between alcoholics and controls at a population level ([Figure 3](#fig3){ref-type="fig"}), although at an individual level the margin may be small ([Supplementary Figure S2](#sup1){ref-type="supplementary-material"}). The latter point suggests that, similar to bipolar disorder^[@bib53]^ and schizophrenia,^[@bib54]^ the contextual cumulative combinatorics of common gene variants and environment^[@bib55]^ has a major role in risk for illness.

Lastly, we have looked at overlap with genes for other major psychiatric disorder domains (bipolar disorders, anxiety disorders, schizophrenias) from our previous studies and provide evidence for shared genes ([Figures 4](#fig4){ref-type="fig"} and [5](#fig5){ref-type="fig"}) as well as shared genetic risk ([Figure 6](#fig6){ref-type="fig"}).

Overall, this work sheds light on the genetic architecture and pathophysiology of alcoholism, provides mechanistic targets for therapeutic intervention and has implications for genetic testing to assess risk for illness before the illness manifests itself clinically, opening the door for enhanced prevention strategies at a young age. As alcoholism is a disease that does not exist if the exogenous agent (alcohol) is not consumed, the use of genetic information to inform lifestyle choices could be quite powerful.

Materials and methods
=====================

Human subject cohorts
---------------------

### Discovery cohort (cohort 1): GWAS for alcohol dependence from Germany

Data for the discovery CFG work (Cohort 1) were obtained from a GWA study of self-reported German descent subjects, consisting of 411 alcohol-dependent male subjects and 1307 population-based controls (663 male and 644 female subjects).^[@bib6]^ Individuals were genotyped using HumanHap 550 BeadChips (Illumina Inc, San Diego, CA, USA). SNPs with a nominal allelic *P*-value \<0.05 were selected for analysis. No Bonferroni correction was performed.

### Test cohort 2 (alcohol dependence, Germany)

An independent test cohort of German descent^[@bib51]^ consisting of 740 alcohol-dependent male subjects and 861 controls (276 male and 585 female subjects) was used for testing the results of the discovery analyses. Individuals were genotyped using Illumina Human610Quad or Illumina Human660w Quad BeadChips (Illumina Inc). The controls were genotyped using Illumina HumanHap550 Bead Chips.

### Test cohort 3 (alcohol dependence, United States) and test cohort 4 (alcohol abuse, United States)

The sample consisted of small nuclear families originally collected for linkage studies, and unrelated individuals, Caucasians and African-American, male and female subjects. The subjects were recruited at five US clinical sites: Yale University School of Medicine (APT Foundation; New Haven, CT, USA), the University of Connecticut Health Center (Farmington, CT, USA), the University of Pennsylvania Perelman School of Medicine (Philadelphia, PA, USA), the Medical University of South Carolina (Charleston, SC, USA) and McLean Hospital (Belmont, MA, USA). All subjects were interviewed using the Semi-Structured Assessment for Drug Dependence and Alcoholism to derive diagnoses for lifetime alcohol dependence, alcohol abuse and other major psychiatric traits according to the DSM-IV criteria. There were 1687 male subjects with alcohol dependence, 366 male subjects with alcohol abuse and 475 male controls. There were 1081 female subjects with alcohol dependence, 234 female subjects with alcohol abuse and 786 female controls ([Table 1](#tbl1){ref-type="table"}). Individuals were genotyped on the Illumina HumanOmni1-Quad v1.0 microarray (988 306 autosomal SNPs). GWAS genotyping was conducted at the Yale Center for Genome Analysis and the Center for Inherited Disease Research. Genotypes were called using the GenomeStudio software V2011.1 and genotyping module version 1.8.4 (Illumina Inc).^[@bib52]^

Gene identification in discovery cohort 1
-----------------------------------------

### Quality control

Genotype data had been filtered using stringent quality-control criteria as described earlier^[@bib51]^ and accounted for call rate, population substructure, cryptic relatedness, minor allele frequency and batch effects.

### Association test in discovery sample

Association testing was performed using PLINK 1.07 (<http://pngu.mgh.harvard.edu/~purcell>)^[@bib56]^ software package. A logistic regression modelling approach was applied to correct for population stratification. Therefore, principal component analysis was conducted considering only independent autosomal SNPs with minor allele frequency \>0.05 and pairwise *R*^2^\<0.05 within a 200-SNP window. LD filtering resulted in a set of 28 505 SNPs used for principal component analysis, which was carried out using GCTA 1.04 (<http://www.complextraitgenomics.com/software/gcta/>).^[@bib57]^ The first two principal components resulting from this analysis were included as covariates in the logistic regression model.

### Assignment of SNPs to genes

Genes corresponding to SNPs were identified initially using the annotation file from the Illumina website (<http://www.illumina.com>, HumanHAP550v3_Gene_Annotation). Next, genes were cross-checked with GeneCards (<http://www.genecards.org>) to ensure that each gene symbol was current. Any gene symbol that matched to a different gene symbol in Gene Cards was checked to verify chromosome number and location match with the original gene, and was replaced with the current GeneCards gene symbol. SNPs from the original annotation files that had no gene matches in the annotation file and UCSC Genome Browser (that is, not falling within an exon or intron of a known gene) were assumed to regulate and thus implicate the gene closest to the SNP location, using the refSNP database from NCBI (<http://www.ncbi.nlm.nih.gov/snp/?SITE=NcbiHome&submit=Go>).

Convergent functional genomic analyses
--------------------------------------

### Databases

We have established in our laboratory (Laboratory of Neurophenomics, Indiana University School of Medicine, [www.neurophenomics.info](http://www.neurophenomics.info)) manually curated databases of all the human gene expression (post-mortem brain, blood and cell cultures), human genetic (association, copy number variants (CNVs) and linkage), animal model genetic and animal model gene expression studies published to date on psychiatric disorders. Only the findings deemed significant in the primary publication, by the study authors, using their particular experimental design and thresholds, are included in our databases. Our databases include only primary literature data and do not include review papers or other secondary data integration analyses to avoid redundancy and circularity. These large and constantly updated databases have been used in our CFG cross-validation and prioritization ([Figure 1](#fig1){ref-type="fig"}).

### Human post-mortem brain, blood and other peripheral tissue gene expression evidence

Information about genes was obtained and imported in our databases searching the primary literature with PubMed (<http://ncbi.nlm.nih.gov/PubMed>), using various combinations of keywords. For this work, the keywords were as follows: alcohol, alcoholism, human, brain, postmortem, lymphocytes, blood, cells and gene expression.

### Human genetic evidence (association, linkage)

To designate convergence for a particular gene, the gene had to have independent published evidence of association or linkage for alcoholism. We sought to avoid using any association studies that included subjects who were also included in our discovery or test cohorts. For linkage, the location of each gene was obtained through GeneCards (<http://www.genecards.org>), and the sex-averaged cM location of the start of the gene was then obtained through <http://compgen.rutgers.edu/old/map-interpolator/>. For linkage convergence, per our previously published criteria, the start of the gene had to map within 5 cM of the location of a marker linked to the disorder with a lod score of ≥2.

### Animal model brain and blood gene expression evidence

For animal model brain and blood gene expression evidence, we have used our own rat model data sets,^[@bib3]^ as well as published reports from the literature curated in our databases.

The rat animal model experimental work from our group was previously described.^[@bib3]^ The experimental approaches used to produce the animal model data for CFG analysis were carried out in two rat lines selectively bred for divergent alcohol preference: inbred alcohol-preferring (iP) versus inbred alcohol-non-preferring (iNP) rats. Following five brain regions were chosen for gene expression studies in these rat lines: the frontal cortex, amygdala, caudate--putamen, nucleus accumbens and hippocampus. Animal studies, as well as human imaging and post-mortem analyses, had previously provided evidence that these regions are implicated in alcoholism.

Data for the analysis came from studies of three experimental paradigms. Paradigm 1 examined basal level of gene expression in the brains of the alcohol-naive iP and iNP lines of rats. This basal comparison was performed to determine innate differences between these two lines with a marked divergence in the willingness to consume alcohol. We hypothesized that the innate differences in gene expression between the iP and iNP would involve some of the genes associated with an increased susceptibility for alcohol dependence. Paradigm 2 examined the effects of chronic 24-h free-choice alcohol consumption on gene expression in iP rats compared with alcohol-naive iP rats. This paradigm looked for gene expression changes in the brain associated with the direct influence of peripherally self-administered alcohol in the genetically susceptible rats. In Paradigm 3, iP rats were allowed to self-infuse alcohol directly into the posterior ventral tegmental area, the originating area of the mesolimbic dopamine system. The advantage of this latter procedure is that it isolates the neurocircuitry involved in alcohol reinforcement, and eliminates the peripheral effects of alcohol. Following the establishment of alcohol self-administration into the posterior VTA, gene expression levels in target brain areas were measured and compared with P rats that received artificial cerebral spinal fluid infusions into the posterior VTA.

### Animal model genetic evidence

To search for mouse genetic evidence (transgenic and QTL) for our candidate genes, we utilized PubMed as well as the Mouse Genome Informatics (<http://www.informatics.jax.org>; Jackson Laboratory, Bar Harbor, ME, USA) database, and used the search 'Genes and Markers\' form to find transgenic in categories for abnormal alcohol consumption, alcohol preference, alcohol aversion, impaired behavioral response to alcohol, hyperactivity elicited by ethanol administration and enhanced behavioral response to alcohol. For QTL convergence, the start of the gene had to map within 5 cM of the location of these markers.

### CFG scoring

We used a nominal *P*-value threshold (having at least one SNP with *P*\<0.05) for including genes from the discovery GWAS in the CFG analysis. No Bonferroni correction was performed.

Internal score: For each of these genes implicated by SNPs, we calculated the percent of SNPs that were nominally significant (ratio of number of nominally significant SNPs over total number of SNPs tested for that gene, multiplied by 100), obtaining a distribution of values. The genes in the top 0.1% of the distribution were given an internal score of 4 points, those in the top 5% of the distribution were given 3 points and the remaining genes all received 2 points. The internal score provides a prioritization of genes based on GWAS results and might prioritize genes that have higher biological relevance and heterogeneity.

External score: Human and animal model data, genetic and gene expression were integrated and tabulated, resulting in a polyevidence CFG score. All six cross-validating lines of evidence (human data and animal model data) were weighted such that evidence from human studies was prioritized 2x over evidence from animal models, gene expression evidence was prioritized 2x over genetic evidence and brain evidence was prioritized 2x over peripheral tissue evidence ([Figure 1](#fig1){ref-type="fig"}). For human genetic evidence, 2 points were assigned if it was from association and 1 point if it was from linkage studies. For animal model genetic evidence, 2 points if it was from transgenic and 1 point if it was from QTL. The maximum possible external score for each gene is 12.

We have capped (one positive study scores maximum points) the hypothesis-driven candidate gene genetic association evidence and animal model genetic (transgenic) lines of evidence, regardless of how many other such studies support that gene, to avoid potential 'popularity\' biases, where some genes are more studied than others. For discovery-driven gene expression studies, we have capped (one positive study scores maximum points) the human post-mortem brain work because of the paucity of brain collections and the fact that such studies often use the same brain bank sources. However, we have not similarly capped the animal model brain and blood gene expression evidence, as such studies are not only discovery-based, but use independent cohorts of animals. These were scored differentially, based on the number of studies showing evidence for a given gene: three or more different studies received full maximum points, two studies 0.75 of maximum points and one study 0.5 of the maximum points. Our group generated data sets for three independent animal studies for this analysis (see above).

The more lines of evidence for a gene---that is, the more times a gene shows up as a positive finding across independent studies, platforms, methodologies and species---the higher its external CFG score ([Figure 1](#fig1){ref-type="fig"}). This is similar conceptually to the Google PageRank algorithm, in which the more links to a page, the higher it comes up on the search prioritization list. It has not escaped our attention that other ways of weighing the lines of evidence may give slightly different results in terms of prioritization, if not in terms of the list of genes *per se*. Nevertheless, we think this simple scoring system provides a good separation of genes, with specificity provided by human data and sensitivity provided by animal model data.

### Prioritizing top alcoholism candidate genes that overlap with a stress-reactive animal model of alcoholism

Stress has been proposed as a driver of alcoholism, notably by Koob and colleagues,^[@bib58],[@bib59]^ as well as by Heilig and colleagues.^[@bib60]^ We have previously identified the circadian clock gene *DBP* as a candidate gene for bipolar disorder,^[@bib61]^ as well as for alcoholism,^[@bib3]^ using a CFG approach. In follow-up work, we established mice with a homozygous deletion of DBP (DBP KO) as a stress-reactive genetic animal model of bipolar disorder and alcoholism.^[@bib4]^ We reported that DBP KO mice have lower locomotor activity, blunted responses to stimulants and gain less weight over time. In response to a stress paradigm that translationally mimics what can happen in humans (chronic stress-isolation housing for 4 weeks, with acute stress, on top of that- experimental handling in week 3), the mice exhibit a diametric switch in these phenotypes. DBP KO mice are also activated by sleep deprivation, similar to bipolar patients, and that activation is prevented by treatment with the mood stabilizer drug valproate. Moreover, these mice show increased alcohol intake following exposure to stress. Microarray studies of brain and blood revealed a pattern of gene expression changes that may explain the observed phenotypes. CFG analysis of the gene expression changes identified a series of candidate genes and blood biomarkers for bipolar disorder, alcoholism and stress reactivity. Subsequent studies by us showed that treatment with the omega-3 fatty acid docosahexaenoic acid (DHA) normalized the gene expression (brain and blood) and behavioral phenotypes of this mouse model, including reducing alcohol consumption.^[@bib5]^

We examined the overlap between the top candidate genes for alcoholism from the current analysis and the top candidate genes from the DBP KO stress mice, thus reducing the list from 135 to 11 ([Figure 4](#fig4){ref-type="fig"}).

### Pathway analyses

IPA 9.0 (Ingenuity Systems, [www.ingenuity.com](http://www.ingenuity.com), Redwood City, CA, USA) was used to analyze the biological roles, including top canonical pathways and diseases, of the candidate genes resulting from our work ([Table 2](#tbl2){ref-type="table"} and [Supplementary Table S2](#sup1){ref-type="supplementary-material"}), as well as used to identify genes in our data sets that are the targets of existing drugs ([Supplementary Table S3](#sup1){ref-type="supplementary-material"}). Pathways were identified from the IPA library of canonical pathways that were most significantly associated with genes in our data set. The significance of the association between the data set and the canonical pathway was measured in 2 ways: (1) a ratio of the number of molecules from the data set that map to the pathway divided by the total number of molecules that map to the canonical pathway is displayed; (2) Fisher\'s exact test was used to calculate a *P*-value determining the probability that the association between the genes in the data set and the canonical pathway is explained by chance alone. We also conducted a KEGG pathway analysis through the Partek Genomic Suites 6.6 software package, Partek Inc, Saint Louis, MO, USA), and GeneGo MetaCore from Thomson Reuters, New York, NY, USA) pathway analyses (<https://portal.genego.com/>).

### Epistasis testing

The test cohort 2 data were used to test for epistatic interactions among the best *P*-value SNPs in the 11 top candidate genes from our work. SNP--SNP allelic epistasis was tested for each distinct pair of SNPs between genes, using the PLINK software package ([Supplementary Table S5](#sup1){ref-type="supplementary-material"}).

Genetic risk prediction
-----------------------

The software package PLINK 1.07 (<http://pngu.mgh.harvard.edu/~purcell>)^[@bib56]^ was used to extract individual genotype information for each subject from the test cohorts 2, 3 and 4 data files.

As we had previously performed for bipolar disorder and schizophrenia, we developed a polygenic GRPS for alcoholism based on the presence or absence of the alleles of the SNPs associated with illness in the discovery GWAS cohort 1, and tested the GRPS in three independent cohorts, from different geographic areas, ethnicities and different types of alcoholism. We tested two panels: a larger panel containing all the nominally significant SNPs in top CFG scoring candidate genes (*n*=135) from the discovery GWAS1 in the top CFG-prioritized genes ([Supplementary Tables S1 and S4](#sup1){ref-type="supplementary-material"}) and a smaller one (*n*=11) containing genes out of the larger panel that were cross-validated using an animal model of alcoholism.

Of note, our genes, SNP panels and choice of affected alleles were based solely on analysis of the discovery GWAS1, which is our discovery cohort, completely independently from the test cohorts. Each SNP has two alleles (represented by base letters at that position). One of them is associated with the illness (affected), the other not (non-affected), based on the odds ratios from the discovery GWAS1. We assigned the affected allele a score of 1 and the non-affected allele a score of 0. A two-dimensional matrix of subjects by GRP panel alleles is generated, with the cells populated by 0 or 1. A SNP in a particular individual subject can have any permutation of 1 and 0 (1 and 1, 0 and 1, 0 and 0). By adding these numbers, the minimum score for a SNP in an individual subject is 0, and the maximum score is 2. By adding the scores for all the alleles in the panel, averaging that and multiplying by 100, we generated for each subject an average score corresponding to a genetic loading for disease, which we call Genetic Risk Predictive Score.^[@bib53],[@bib54]^

To test for significance, a one-tailed *t*-test with unequal variance was performed between the alcoholic subjects and the control subjects, looking at differences in GRPS.

### Receiver operating characteristic curves

Receiver operating characteristic curves were plotted using IBM SPSS Statistics 21. Diagnosis was converted to a binary call of 0 (control) or 1 (alcohol-dependent or abuser) and entered as the state variable, with calculated GRPS entered as the test variable ([Supplementary Figure S2](#sup1){ref-type="supplementary-material"}).

Results
=======

Top candidate genes
-------------------

To minimize false-negatives, we initially cast a wide net, using as a filter a minimal requirement for a gene to have both some GWAS evidence and some additional independent evidence. Thus, out of the 6085 genes with at least a SNP at *P*\<0.05 in the discovery GWAS cohort 1, we generated a list of 3142 genes that also had some additional line of evidence (human or animal model data), implicating them in alcoholism (CFG score ≥2.5 (≥2 internal)+(≥0.5 external)). This suggests, using these minimal thresholds and requirements, that the repertoire of genes potentially involved directly or indirectly in alcohol consumption and alcoholism may be quite large, similar to what we have previously seen for bipolar disorder^[@bib62]^ and schizophrenia.^[@bib54]^ To minimize false-positives, we used an internal score based on percent of SNPs in a gene that were nominally significant, with 4 points for those in the top 0.1% of the distribution (*n*=77), 3 points for those in the top 5% of the distribution (*n*=561) and 2 points for the rest of the nominally significant SNPs (*n*=5447). We then used the CFG analysis and scoring integrating multiple lines of evidence to prioritize this list of genes ([Figure 1](#fig1){ref-type="fig"}) and focused our subsequent analyses on only the top CFG scoring candidate genes. Overall, 135 genes had a CFG score of 8 and above (≥50% of maximum possible score of 16).

Of note, there was no correlation between CFG prioritization and gene size, thus excluding a gene-size effect for the observed enrichment ([Supplementary Figure S1](#sup1){ref-type="supplementary-material"}).

Biological pathways and drug targets
------------------------------------

Pathway analyses were carried out on the top candidate genes ([Table 2](#tbl2){ref-type="table"}). Notably, Gαi signaling, cocaine addiction and transmission of nerve impulses were the top biological pathways in alcoholism, which may be informative for treatments and drug discovery efforts by pharmaceutical companies. Of note, these top candidate genes were identified and prioritized only for evidence for alcoholism before pathway analyses; therefore, the overlap with cocaine addiction is a completely independent result, suggesting a shared drive and neurobiology. Consistent with that, two of our 135 top candidate genes for alcoholism (CPE and VWF) had SNPs with *P*\<10^−5^ in a recent GWAS of cocaine addiction.^[@bib63]^

Some of the top alcohol candidate genes have prior evidence of being modulated by the omega-3 fatty acid DHA in our DBP mouse animal model ([Table 3](#tbl3){ref-type="table"} and [Supplementary Table S1](#sup1){ref-type="supplementary-material"}). That is of particular interest, as we have previously shown that treatment with the omega-3 fatty acid DHA decreased alcohol consumption in that animal model, as well as in another independent animal model, the alcohol-preferring P rats.^[@bib5]^ Omega-3 fatty acids, particularly DHA, have been described to have alcoholism, mood, psychosis and suicide-modulating properties, in preclinical models as well as some human clinical trials and epidemiological studies. For example, deficits in omega-3 fatty acids have been linked to increased depression and aggression in animal models^[@bib64],[@bib65]^ and humans.^[@bib66],[@bib67]^ DHA prevents ethanol damage *in vitro* in rat hippocampal slices.^[@bib68]^ Omega-3 supplementation can prevent oxidative damage caused by prenatal alcohol exposure in rats.^[@bib69]^ Of note, deficits in DHA have been reported in erythrocytes^[@bib70]^ and in the post-mortem orbitofrontal cortex of patients with bipolar disorder, and were greater in those that had high versus those that had low alcohol abuse.^[@bib71]^ Low DHA levels may be a risk factor for suicide.^[@bib72],[@bib73]^ Omega-3 fatty acids have been reported to be clinically useful in the treatment of both mood^[@bib74],\ [@bib75],\ [@bib76],\ [@bib77]^ and psychotic disorders.^[@bib78],\ [@bib79],\ [@bib80]^

Other existing pharmacological drugs that modulate alcohol candidate genes identified by us include, besides benzodiazepines, dopaminergic agents, glutamatergic agents, serotonergic agents, as well as statins ([Supplementary Table S3](#sup1){ref-type="supplementary-material"}).

Genetic risk prediction score
-----------------------------

Once the genes involved in a disorder are identified, and prioritized for likelihood of involvement, then an obvious next step is developing a way of applying that knowledge to genetic testing of individuals to determine risk for the disorder. On the basis of our identification of top candidate genes described above using CFG, we pursued a polygenic panel approach, with digitized binary scoring for presence or absence, similar to the one we have devised and used in the past for biomarkers testing^[@bib53],[@bib81]^ and for genetic testing in bipolar disorder^[@bib53]^ and schizophrenia.^[@bib54]^ Somewhat similar approaches but without CFG prioritization, attempted by other groups, have been either unsuccessful^[@bib82]^ or have required very large panels of markers.^[@bib83]^

We chose all the nominally significant *P*-value SNPs (*P*\<0.05) in each of our top CFG-prioritized genes (*n*=135 with CFG score ≥8; [Supplementary Table S1](#sup1){ref-type="supplementary-material"}) in the GWAS1 data set used for discovery, and assembled a GRPS-135 panel out of those SNPs ([Table 4](#tbl4){ref-type="table"}). We then tested the GRPS-135 in the independent German test cohort 2, based on the presence or absence of the alleles of the SNPs associated with the illness, comparing the alcoholic subjects to controls ([Table 4](#tbl4){ref-type="table"}), and showed that, although there was a trend, we were not able to distinguish alcoholics from controls in both independent test cohorts.

We then prioritized a smaller panel of 11 genes ([Table 3](#tbl3){ref-type="table"}) out of this larger panel, by using as a cross-validator the top genes from a stress-reactive mouse animal model for alcoholism, the DBP knockout mouse^[@bib4]^ ([Figure 4](#fig4){ref-type="fig"}). The small panel (GRPS-11) showed more robust results than the larger panel ([Table 4](#tbl4){ref-type="table"}), suggesting that it captures the key behaviorally relevant genes.

Discussion
==========

Our CFG approach helped to prioritize a very rich-in-signal and biologically interesting set of genes ([Table 3](#tbl3){ref-type="table"} and [Supplementary Table S1](#sup1){ref-type="supplementary-material"}). Some, such as SNCA, CPE, DRD2 and GRM3, have weaker evidence based on the GWAS data but strong independent evidence in terms of gene expression studies and other prior human or animal genetic work. Conversely, some of the top previous genetic findings in the field,^[@bib84]^ such as ADH1C^[@bib85]^ (CFG score of 9), GABRA2^[@bib86]^ (CFG score of 8), as well as AUTS2 (CFG score of 7), CHRM2 and KCNJ6 (CFG scores of 4) have fewer different independent lines of evidence, and thus received a lower CFG prioritization score in our analysis ([Supplementary Table S1](#sup1){ref-type="supplementary-material"}), although they are clearly involved in alcoholism-related processes. Whereas we cannot exclude that more recently discovered genes have had less hypothesis-driven work performed and thus might score lower on CFG, it is to be noted that the CFG approach integrates predominantly non-hypothesis-driven, discovery-type data sets, such as GWAS data, linkage, quantitative traits loci and, particularly, gene expression. We also cap each line of evidence from an experimental approach ([Figure 1](#fig1){ref-type="fig"}), to minimize any 'popularity\' bias, whereas multiple studies of the same kind are conducted on better-established genes. In the end, it is gene-level reproducibility across multiple approaches and platforms that is built into the approach and gets prioritized most by CFG scoring during the discovery process. Our top results subsequently show good reproducibility and predictive ability in independent cohort testing, the litmus test for any such work.

At the very top of our list of candidate genes for alcoholism, with a CFG score of 13, we have SNCA, a pre-synaptic chaperone that has been reported to be involved in modulating brain plasticity and neurogenesis, as well as neurotransmission, primarily as a brake.^[@bib87],[@bib88]^ On the pathological side, low levels of SNCA might offer less protection against oxidative stress,^[@bib89]^ whereas high levels of SNCA may have a role in neurodegenerative diseases, including in Parkinson disease. SNCA has been identified as a susceptibility gene for alcohol cravings^[@bib7]^ and response to alcohol cues.^[@bib90]^ The evidence provided by our data and other previous human genetic association studies suggest a genetic rather than purely environmental (alcohol consumption and stress) basis for its alteration in disease, and its potential utility as trait rather than purely state marker.

Alcoholics carry a genetic variant that leads to reduced baseline expression of *SNCA*.^[@bib8]^ SNCA is also downregulated in expression in the frontal cortex and caudate--putamen of inbred alcohol-preferring rats,^[@bib17]^ as well as in the brain (amygdala) and blood of our stress-reactive DBP animal model of alcoholism, before exposure to any alcohol. SNCA is upregulated in expression in blood in human alcoholism,^[@bib12],[@bib13]^ as well as in the blood of monkeys consuming alcohol, and in rats after alcohol administration.^[@bib3]^ Thus, it may serve as a blood biomarker. Overall, we may infer that, whereas low levels of SNCA may predispose to cravings for alcohol and consequent alcoholism, possibly mediated through increased neurobiological activity and drive (*the SNCA deficit hypothesis*), excessive alcohol consumption then increases SNCA expression beyond that seen in non-alcohol-consuming controls, potentially compounding risk for neurodegenerative diseases in individuals that have mutations that lead to its aggregation. This observation is also biologically consistent with the fact that dementia is often observed late in the course of alcohol dependence.

*GFAP* (glial fibrillary acidic protein), a top candidate gene with a CFG score of 9.5, is an astrocyte intermediate filament-type protein involved in neuron--astrocyte interactions, cell adhesion, process formation and cell--cell communication. It is decreased in expression in post-mortem brain of alcoholics, but increased in expression in brains of animal models of predisposition to alcoholism, before exposure to alcohol ([Table 3](#tbl3){ref-type="table"}). This is consistent with a model for increased physiological robustness in individuals predisposed to alcoholism,^[@bib3]^ as well as with the neurodegenerative consequences of protracted alcohol use.

*DRD2* (dopamine receptor D2), another top candidate gene with a CFG score of 9, has prior human genetic association evidence. It is reduced in expression in the frontal cortex in the human brain from alcoholics, as well as in the DBP animal model before any exposure to alcohol. One possible interpretation would be that lower levels of dopamine receptors are associated with reduced dopaminergic signaling and anhedonia, leading individuals to overcompensate by alcohol and drug abuse. Another interpretation, consistent with the low SNCA and consequently higher neurotransmitter (including dopamine) levels, would be that these individuals are in fact in a compulsive, hyperdopaminergic state, which drives them to hedonic activities and leads to compensatory homeostatic downregulation of their DRD2 receptors. Consistent with this later scenario, mice that have a constitutive knockout of their DRD2 receptors, not because of a hyperdopaminergic state, in fact consume less alcohol,^[@bib29]^ unless they are exposed to stress.^[@bib91]^

Another top candidate gene, *GRM3*, is also involved in neurotransmitter signaling. Prior evidence in the field had implicated another metabotropic glutamate receptor, GRM2.^[@bib92]^

Other top candidate genes in the panel (*MOBP*, *MBP* and *MOG*) are involved in myelination ([Table 3](#tbl3){ref-type="table"}). They are decreased in expression in the prefrontal cortex of human alcoholics, as well as in our stress-reactive DBP animal model of alcoholism, before exposure to any alcohol. Decreased myelination may lead to decreased connectivity. Interestingly, MOBP and MBP are increased in expression in the amygdala in the DBP mice, opposite to the direction of change in the PFC, consistent with a frontal deactivation and a limbic hyperactivity, which could lead to impulsivity.

Epistasis testing of top candidate genes for alcoholism
-------------------------------------------------------

For the top 11 candidate genes, best *P*-value SNPs from GWAS1 were used to test for gene--gene interactions in GWAS2 ([Supplementary Table S5](#sup1){ref-type="supplementary-material"}). Nominally significant interactions were found between SNPs in SNCA and RXRG, DRD2 and SYT1, MOBP and TIMP2. As a caveat, the *P*-value was not corrected for multiple comparisons. The corresponding genes merit future follow-up work to elucidate the biological and pathophysiological relevance of their interactions.

Pathways and mechanisms
-----------------------

Our pathway analysis ([Table 2](#tbl2){ref-type="table"} and [Supplementary Table S2](#sup1){ref-type="supplementary-material"}) results are consistent with the accumulating evidence about the role of neuronal excitability and signaling in alcoholism.^[@bib83],[@bib93],[@bib94]^

Overlap with other psychiatric disorders
----------------------------------------

Despite using lines of evidence for our CFG approach that have to do only with alcoholism, the list of genes identified has a notable overlap at a pathway analysis level ([Table 2B](#tbl2){ref-type="table"} and [Supplementary Table S2B](#sup1){ref-type="supplementary-material"}) and at a gene level ([Figures 4](#fig4){ref-type="fig"} and [5](#fig5){ref-type="fig"}) with other psychiatric disorders. This is a topic of major interest and debate in the field. We demonstrate an overlap between top candidate genes for alcoholism and top candidate genes for schizophrenia, anxiety and bipolar disorder, previously identified by us through CFG ([Figure 4](#fig4){ref-type="fig"}), thus providing a possible molecular basis for the frequently observed clinical comorbidity and interdependence between alcoholism and those other major psychiatric disorders, as well as cross-utility of pharmacological agents. Moreover, we tested in alcoholics genetic risk predictive panels for bipolar disorder^[@bib53]^ and for schizophrenia^[@bib54]^ generated in previous studies by us, and show that they are significantly different in alcoholics versus controls ([Figure 6](#fig6){ref-type="fig"}), beyond the overlap in genes with alcohol. There seems to be an increased genetic load for bipolar disorder, consistent with increased drive, and a decreased genetic load for schizophrenia, consistent with increased connectivity before alcohol use. These results led us to develop a heuristic, testable model of alcoholism ([Figure 5](#fig5){ref-type="fig"}). Some people may drink to be calm, mitigating the effects of stress and anxiety, some people may drink to be happy, the common drive with bipolar disorder, and some people may drink to be drunk, to disconnect from reality and/or get unstuck from internal obsessions and ruminations.

Genetic risk prediction
-----------------------

Of note, our SNP panels and choice of affected alleles were based solely on analysis of the discovery GWAS, completely independently from the test cohorts. Our results show that a relatively limited and well-defined panel of SNPs identified based on our CFG analysis could differentiate between alcoholism subjects and controls in three independent cohorts. The fact that our genetic testing worked for both alcohol dependence and alcohol abuse suggests that these two diagnostic categories are actually overlapping, supporting the DSM-V reclassification of a single category of  alcohol use disorders.

Reproducibility among studies
-----------------------------

Our work provides striking evidence for the advantages, reproducibility and consistency of gene-level analyses of data, as opposed to SNP level analyses, pointing to the fundamental issue of genetic heterogeneity at a SNP level. In fact, it may be that the more biologically important a gene is for higher mental functions, the more heterogeneity it has at a SNP level and the more evolutionary divergence, for adaptive reasons. On top of that, CFG provides a way to prioritize genes based on disease relevance, not study-specific effects (that is, fit-to-disease as opposed to fit-to-cohort). Reproducibility of findings across different studies, experimental paradigms and technical platforms is deemed more important (and scored as such by CFG) than the strength of finding in an individual study (for example, *P*-value in a GWAS).

Potential limitations and confounds
-----------------------------------

The GWAS study (cohort 1) on which our discovery was based contained males as probands but contained males and females as controls. This was the case for the German test cohort (cohort 2) as well. It is possible that some of the nominally significant SNPs identified in the discovery GWAS have to do with gender differences rather than to alcoholism *per se*, or at least may have to do with male alcoholism. Stratification across gender and ethnicities may also be a factor in our test cohorts 3 and 4 ([Table 1](#tbl1){ref-type="table"}). The issue of possible ethnicity differences in alleles, genes and the consequent neurobiology may need to be explored more in the future, with larger sample sizes, and with environmental and cultural factors taken into account. However, the use of a CFG approach using evidence from other studies of alcoholism, including animal model studies, to prioritize the findings decreases the likelihood that our final top results are ethnicity- or gender-related. Of note, our GRPS predictions separate alcoholics from controls in independent test cohorts, in both genders, and in fact work even better at separating female alcoholics from female controls ([Figure 3](#fig3){ref-type="fig"}). Moreover, a series of individual genes from the panel, not just SNCA, separates alcoholics from controls in independent cohorts ([Table 5](#tbl5){ref-type="table"}).

The conversion from SNPs to genes as part of our discovery assumed the rule of proximity---that is, an intragenic SNP implicates the gene inside which it falls, or if it falls into an intergenic region, it implicates the most proximal gene to it. That may not be true in reality in all cases, generating potentially false-positives and false-negatives. However, the convergent approach and focus on the top CFG scoring genes reduce the likelihood of false-positives.

The only SNP for SNCA that was present/tested for in cohorts 3 and 4 (rs17015888) was relatively far away upstream (0.13 MB) from SNCA. However, no other known genes are present in that region, SNCA is the closest gene, and the distance is well within the range of known examples of regulatory regions (enhancers). In addition, the risk allele for this SNP (G/G) seems to be the major variant in the population ([Supplementary Table S6](#sup1){ref-type="supplementary-material"}), suggesting that this allele *per se* is evolutionarily advantageous, when not coupled with the exogenous ingestion of alcohol.

A relatively large list of genes (*n*=6085) was implicated by nominally significant SNPs from the discovery GWAS. There is a risk that out of such a large list CFG will find something to prioritize. We have tried to mitigate that by developing an internal score for each gene based on the proportion of SNPs tested in a gene that were nominally significant. Moreover, in the end, we tested the reproducibility and predictive ability of our top findings in multiple independent cohorts, which is the ultimate litmus test for any genetic or biomarker study.

Conclusion
==========

Overall, whereas multiple mechanistic entry points may contribute to alcoholism pathogenesis, it is likely at its core a disease of an exogenous agent (alcohol) modulating different mind domains/dimensions (anxiety, mood and cognition),^[@bib95]^ precipitated by environmental stress on a background of genetic vulnerability ([Figure 5](#fig5){ref-type="fig"}). The degree to which various mind domains/dimensions are affected in different individuals is a fertile area for future research into subtypes of alcoholism and lends itself to personalization of diagnosis and treatment, by integrating genetic data, blood gene expression biomarker data and clinical data. Lastly, it is important to note that individuals with a predisposition to alcoholism but no exposure to alcohol may in fact have a robust physiology and strong neurobiological drive that can be harnessed for other, more productive endeavors.

This work is, in essence, a field-wide collaboration. We would like to acknowledge our debt of gratitude for the efforts and results of the many other groups, cited in our paper, who have conducted and published studies (genetic and gene expression) in alcoholism. With their arduous and careful work, a convergent approach, such as ours, is possible. We would particularly like to thank the subjects who volunteered to participate in these studies. Without their generous contribution, such work to advance the understanding of alcoholism and help others would not be possible. This work was supported by an NIH Directors\' New Innovator Award (1DP2OD007363) and a VA Merit Award (1I01CX000139-01) to ABN, as well as by NIH grants R01 DA12690, R01 DA12849, R01 AA11330, R01 and AA017535 to JG and collaborators, and by grant FKZ 01GS08152 from the National Genome Research Network of the German Federal Ministry of Education and Research to MR and collaborators.
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![Convergent Functional Genomics.](tp201429f1){#fig1}

![Top candidate genes for alcoholism.](tp201429f2){#fig2}

![Genetic Risk Prediction using a panel of top candidate genes for alcoholism (GRPS-11). Testing in independent cohorts 3 and 4.](tp201429f3){#fig3}

![Overlap of alcoholism versus other major psychiatric disorders. Top candidate genes for alcoholism identified by CFG (*n*=135) in the current study versus top candidate genes for other psychiatric disorders and a stress-driven animal model of alcoholism (DBP knockout mouse) from our previous work.](tp201429f4){#fig4}

![Mindscape (mental landscape)-dimensional view of genes that may be involved in alcoholism and other major psychiatric disorders.](tp201429f5){#fig5}

![Genetic load for bipolar disorder and schizophrenia in alcoholism. A total of 34 out of 66 SNPs in our alcohol GRPS-11 panel (current work; in *n*=10 genes), 42 out of 224 SNPs in our bipolar GRPS^[@bib53]^ (in *n*=34 genes) and 151 out of 542 SNPs in our schizophrenia GRPS^[@bib54]^ (in *n*=35 genes) were present and tested in the alcohol cohorts 3 and 4. See also [Supplementary Table S7](#sup1){ref-type="supplementary-material"}.](tp201429f6){#fig6}

###### Discovery and test cohorts

                                                   *Alcohol dependence*                     *Control*
  ------------------------------------------------ ---------------------- ----------------- ----------------
  *Discovery cohort 1 GWAS Germany*                                                         
   Male                                            411                                      663
   Female                                          0                                        644
   Ethnicity                                       All Caucasians                           All Caucasians
                                                                                             
  *Test cohort 2 Germany*                                                                   
   Male                                            740                                      276
   Female                                          0                                        585
   Ethnicity                                       All Caucasians                           All Caucasians
                                                   *Alcohol dependence*   *Alcohol abuse*   *Control*
  *Test cohorts 3 and 4, United States*                                                     
   Male                                            1687                   366               475
   Female                                          1081                   234               786
   Male ethnicity (Caucasian/African-American)     802/885                201/165           168/307
   Female ethnicity (Caucasian/African-American)   471/610                123/111           220/566

Abbreviation: GWAS, genome-wide association study.

###### Pathway analyses: (A) biological pathways, (B) disease and disorders

                                                                           *Ingenuity pathways*              *KEGG pathways*              *GeneGO pathways*                                                                                                                                                            
  ------------------------------------------------------------------------ ---------------------- -------------------------------------- ------------------- --------------- ------------------------------------------ --------- ------------- ---------------------------------------------------------- ----------- -------
  *GRPS-11*, top DBP KO genes out of CFG score ≥8.0 genes (*n*=11 genes)   1                                  GαI signaling                   4.68E−05        3/135 (0.022)              Cocaine addiction              11.9589    6.40226E−06   Neurophysiological process_Transmission of nerve impulse   6.010E−06   6/212
                                                                           2                             cAMP-mediated signaling              2.64E−04        3/226 (0.013)                 Gap junction                5.71209    0.00330577              Development_Neurogenesis in general              9.163E−04   4/192
                                                                           3                       G-protein-coupled receptor signaling       4.37E−04        3/276 (0.011)            Glutamatergic synapse            5.21128    0.00545466              Reproduction_GnRH signaling pathway              6.603E−03   3/166
                                                                           4                            14-3-3-mediated signaling             2.14E−03        2/121 (0.017)             Dopaminergic synapse            5.0126     0.00665355             Transport_Synaptic vesicle exocytosis             7.762E−03   3/176
                                                                           5                          Synaptic long-term depression           3.33E−03        2/161 (0.012)   Neuroactive ligand--receptor interaction  3.62169     0.0267375            Development_Neurogenesis_Synaptogenesis            8.258E−03   3/180

                                                                            *Ingenuity*              *GeneGO*                                                                                   
  ------------------------------------------------------------------------ ------------- --------------------------------- ---------------------- ---- ---------------------------- ----------- ---------
  *GRPS-11*, top DBP KO genes out of CFG score ≥8.0 genes (*n*=11 genes)         1              Hereditary disorder         1.66E−08 to 1.29E−02   9          Schizophrenia          1.476E−10   11/1033
                                                                                 2             Neurological disease         1.66E−08 to 1.64E−02   10            Suicide             1.076E−09    6/151
                                                                                 3            Psychological disorders       1.66E−08 to 1.53-02    9    Depressive disorder, major   2.106E−09   10/966
                                                                                 4                    Cancer                1.90E−08 to 1.82E−02   10        Bipolar disorder        2.983E−09    9/706
                                                                                 5        Skeletal and muscular disorders   1.50E−07 to 1.34E−02   6            Alcoholism           3.468E−09    7/291

Abbreviations: CFG, Convergent Functional Genomics; DBP, D-box-binding protein. Pathway analyses of top candidate genes.

###### Top candidate genes for alcoholism

  *Gene* *symbol/name*                                                                                *Discovery GWAS1* *best* P*-value SNP*   *Internal score nominally significant SNPs/total SNPs tested (% significant)*  *Human* *genetic evidence*                                          *Human post-mortem brain expression evidence*              *Human* *peripheral expression evidence*                                                       *Animal model genetic evidence*                                         *Animal model brain expression evidence*                                              *Animal model peripheral (blood) expression evidence*             *CFG* *score*   *DBP* *stress*^[@bib4]^   *DBP* *stress* *DHA^[@bib5]^*
  -------------------------------------------------------------------------------------------------- ---------------------------------------- ------------------------------------------------------------------------------- ------------------------------------------------------------------- ---------------------------------------------------------- ---------------------------------------------------------------------------------------------- ----------------------------------------------------------------------- ------------------------------------------------------------------------------------- ----------------------------------------------------------------- --------------- ------------------------- -------------------------------
  *[SNCA]{.ul},* synuclein alpha (non A4 component of amyloid precursor)                                        0.02363 rs17015982                                            2 4/68 (5.89%)                                  Association^[@bib7],[@bib8]^                                        \(D\) PFC^[@bib8],\ [@bib9],\ [@bib10]^ (I) FC^[@bib11]^   \(I\) Blood^[@bib12]^ (I) Blood^[@bib13]^ (I) Serum^[@bib14]^ DNA hypermethylation^[@bib15]^   QTL^[@bib16]^                                                           \(D\) FC, CP^[@bib17]^ (I) HIP P1 AMY P3^[@bib3]^                                     \(I\) Blood male adult cynomolgus monkeys^[@bib18]^               13              \(D\) AMY, blood          \(I\) Blood
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       
  *GFAP,* glial fibrillary acidic protein                                                                        0.01052 rs744281                                             3 4/12 (33.34%)                                 Linkage^[@bib19]^                                                   \(D\) FC^[@bib9],[@bib11],[@bib20]^                                                                                                                                                                                               \(I\) FC^[@bib21]^ HIP, NAC, PFC P1^[@bib3]^                                                                                                            9.5             \(I\) AMY                  
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       
  *DRD2*, dopamine receptor D2                                                                                  0.03652 rs4938019                                             2 2/46 (4.35%)                                  Association^[@bib22],\ [@bib23],\ [@bib24],\ [@bib25],\ [@bib26]^   \(D\) FC, CP^[@bib27]^ (D)^[@bib28]^                                                                                                                      (Transgenic) alcohol aversion decreased alcohol consumption^[@bib29]^                                                                                                                                                           9               \(D\) PFC                 \(I\) AMY
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       
  *GRM3*, glutamate receptor, metabotropic 3                                                                     0.001126 rs41440                                            2 15/133 (11.28%)                                Linkage^[@bib30],[@bib31]^                                          \(D\) HIP^[@bib32]^                                                                                                                                                                                                               \(I\) NAC^[@bib33]^ (D) FC^[@bib34]^ (D) CP P2^[@bib3]^                                                                                                 9               \(I\) AMY                  
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       
  *MBP*, myelin basic protein                                                                                   0.006503 rs1124941                                           2 16/109 (14.68%)                                                                                                    \(D\) FC^[@bib11]^                                                                                                                                                                                                                \(I\) PFC^[@bib35]^ (D) cerebellum^[@bib36]^ delayed expression^[@bib37]^             \(D\) CG-4 glial cells rat brain^[@bib38]^                        8.5             \(D\) PFC (I) AMY         \(D\) Blood (I) HIP
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       
  *MOBP*, myelin-associated oligodendrocyte basic protein                                                        0.01231 rs562545                                             2 2/43 (4.66%)                                                                                                      \(D\) FC^[@bib11]^                                                                                                                                        QTL^[@bib39]^                                                           \(I\) PFC^[@bib35]^ (D) NAC^[@bib40]^ (I) whole brain^[@bib41]^ (I) PFC P1^[@bib3]^                                                                     8.5             \(D\) PFC (I) AMY         \(D\) Blood (I) HIP
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       
  *GNAI1*, guanine nucleotide binding protein (G protein), alpha-inhibiting activity polypeptide 1            **0.00059** rs12706724                                         2 11/66 (16.67%)                                 Linkage^[@bib42],[@bib43]^                                          \(D\) HIP^[@bib32]^                                                                                                                                                                                                               \(D\) NAC P3^[@bib3]^                                                                                                                                   8               \(D\) PFC                  
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       
  *MOG*, myelin oligodendrocyte glycoprotein                                                                    0.01429 rs3117292                                             2 3/19 (15.79%)                                                                                                     \(D\) FC, HIP^[@bib11],[@bib32]^                                                                                                                                                                                                  \(D\) VTA^[@bib44]^ (I) PFC^[@bib35]^ (I) PFC P1^[@bib3]^                                                                                               8               \(D\) PFC                 \(I\) HIP
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       
  *RXRG*, retinoid X receptor, gamma                                                                           0.005815 rs10800098                                            2 1/37 (2.71%)                                  Linkage^[@bib45]^                                                   \(D\) FC^[@bib11]^                                                                                                                                                                                                                \(I\) CP P3^[@bib3]^                                                                                                                                    8               \(D\) PFC                  
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       
  *SYT1,* synaptotagmin I                                                                                       0.04139 rs1245810                                             2 7/117 (5.99%)                                                                                                     \(D\) NAC^[@bib46]^                                                                                                                                                                                                               \(D\) FC^[@bib34]^ (D) HIP^[@bib47]^                                                  \(I\) Cultured neurons^[@bib48]^ (I) Cortical neurons^[@bib49]^   8               \(D\) PFC                 \(D\) AMY
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       
  *TIMP2,* TIMP metallopeptidase inhibitor 2                                                                    0.04309 rs7502935                                               2 1/25 (4%)                                   Linkage^[@bib45]^                                                   \(D\) FC, HIP, NAC^[@bib32],[@bib46],[@bib50]^                                                                                                                                                                                    \(I\) VTA^[@bib44]^                                                                                                                                     8               \(D\) PFC                 \(D\) Blood

Abbreviations: AMY, amygdala; Association, association evidence; CFG, convergent functional genomics; CP, caudate--putamen; D, decreased in expression; DBP, D-box-binding protein; DHA, docosahexaenoic acid; GWAS, genome-wide association study; HIP, hippocampus; I, increased; Linkage, linkage evidence; NAC, nucleus accumbens; P1, paradigm 1; P2, Paradigm 2; P3, paradigm 3 in the Rodd *et al*;^[@bib3]^ PFC, prefrontal cortex; QTL, quantitative trait loci; SNP, single-nucleotide length polymorphism; TG, transgenic; VT, ventral tegmentum; VTA, ventral tegmental area.

Top genes with a CFG score of 8 and above that overlapped with top genes from the stress-reactive animal model are shown (*n*=11; [Figure 4](#fig4){ref-type="fig"}). Best *P*-value SNP within the gene or flanking regions is depicted. A more complete list of genes with CFG score of 8 and above (*n*=135) is available in the [Supplementary Information](#sup1){ref-type="supplementary-material"} section ([Supplementary Table S1](#sup1){ref-type="supplementary-material"}). Underlined gene symbol represents means gene is a blood biomarker candidate. Bold *P*-values \<0.001.

###### Genetic Risk Prediction Score (GRPS)-Panels from Discovery Cohort 1

                                                                                                                                                         *Test in cohort 2* *alcohol-dependent versus control*
  ----------------------------------------------------------------------------------------------------------------------------------------------------- -------------------------------------------------------
  *GRPS-135*,  genes with CFG score of ≥8  all nominally significant SNPs in each gene (*n*=713)                                                                    *P*=0.053 (135 genes, 713 SNPs)
  *GRPS-11,* top animal model (DBP mouse) prioritized genes  out of genes with CFG score of ≥8  all nominally significant SNPs in each gene (*n*=66)                 *P*=0.041 (11 genes, 66 SNPs)
                                                                                                                                                                                    
                                                                                                                                                         *Test in cohort 3* *alcohol-dependent versus control*
  GRPS-11,  top animal model (DBP mouse) prioritized genes  out of genes with CFG score of ≥8  all nominally significant SNPs in each gene (*n*=66)             *P*=0.00012 (10 genes, 34 SNPs present)
  *GRPS-SNCA*,  top CFG gene  all nominally significant SNPs in it (*n*=4)                                                                                 *P*=0.000013 (1 gene, 1 SNP *rs17015888* present)
                                                                                                                                                                                    
                                                                                                                                                           *Test in cohort 4* *alcohol abuse versus control*
  *GRPS-11,*  top animal model (DBP mouse) prioritized genes  out of genes with CFG score of ≥8  all nominally significant SNPs in each gene (*n*=66)           *P*=0.0094 (10 genes, 34 SNPs present)
  *GRPS-SNCA,*  top CFG gene  all nominally significant SNPs in it (*n*=4)                                                                                  *P*=0.023 (1 gene, 1 SNP *rs17015888* present)

Abbreviations: CFG, Convergent Functional Genomics; DBP, DNA-box-binding protein; SNCA, synuclein alpha; SNP, single-nucleotide length polymorphism.

Differentiation between alcoholics and controls in three independent test cohorts using, GRPS-135, a panel composed of all the nominally significant SNPs from GWAS1 in the top candidate genes prioritized by CFG; GRPS-11, a panel additionally prioritized by a stress-reactive animal model for alcoholism, the DBP KO-stressed mouse; and GRPS-SNCA, the top candidate gene from our analyses. *P*-values depict one-tailed *t*-test results between alcoholics and controls.

###### Individual top genes and genetic risk prediction in independent cohorts

  *Gene/SNPs*                                                                                                                                                                                           *CFG score*  *Mean GRPS*   t*-test*   
  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ------------- ------------- ---------- -------------
  *(A) Test cohort 2*                                                                                                                                                                                                                         
  ** ***Panel of 11 top genes*                                                                                                                                                                                                                
  **  **66 SNPs                                                                                                                                                                                             ≥8       53.98         54.61      *0.041*
  * SNCA*                                                                                                                                                                                                                                      
  **  **rs7668883   rs17015888   rs17015982   rs6532183                                                                                                                                                     13       93.93         92.84      0.086
  * GFAP*                                                                                                                                                                                                                                     
  **  **rs3744473   rs3169733   rs736866   rs744281                                                                                                                                                         9.5      63.99         64.69      0.303
  * DRD2*                                                                                                                                                                                                                                     
  **  **rs4648317   rs4938019                                                                                                                                                                                9       13.07         15.51      *0.024*
  * GRM3*                                                                                                                                                                                                                                     
  **  **rs17160519   rs6944937   rs13236080   rs17315854   rs12668989   rs41440   rs2373124   rs13222675   rs2708553   rs12673599   rs4236502   rs1554888   rs10499898   rs1527769   rs17161018              9       55.44         54.94      0.271
  * MBP*                                                                                                                                                                                                                                      
  **  **rs470131   rs2282566   rs736421   rs1789094   rs9951586   rs1667952   rs1789105   rs1789103   rs1812680   rs1789139   rs4890912   rs9947485   rs1562771   rs1015820   rs1124941   rs11877526        8.5      44.92         47.07      ***0.002***
  * MOBP*                                                                                                                                                                                                                                     
  **  **rs562545   rs2233204                                                                                                                                                                                8.5      49.88         49.93      0.487
  ** ***GNAI1*                                                                                                                                                                                                                                
  **  **rs4731111   rs6466884   rs7803811   rs17802148   rs7805663   rs10486920   rs2523189   rs2886611   rs2886609   rs12706724   rs4731302                                                                 8       72.97         72.71      0.393
  * MOG*                                                                                                                                                                                                                                      
  **  **rs3117292   rs2747442   rs3117294                                                                                                                                                                    8       34.53         34.56      0.493
  * RXRG*                                                                                                                                                                                                                                     
  **  **rs10800098                                                                                                                                                                                           8       6.04          5.27       0.174
  * SYT1*                                                                                                                                                                                                                                     
  **  **rs1569033   rs10735416   rs1245810   rs1245819   rs1268463   rs1245840   rs10861755                                                                                                                  8       39.16         40.89      0.113
  * TIMP2*                                                                                                                                                                                                                                    
  **  **rs7502935                                                                                                                                                                                            8       67.65         70.61      *0.038*

                                                    *Gene/SNPs*                                                    *CFG score*   *Mean GRPS*   t*-test*                           
  --------------------------------------------------------------------------------------------------------------- ------------- ------------- ---------- ------- ---------------- ----------
                                            *(B) Test cohorts 3 and 4*                                                                                                            
                                             * Panel of 10 top genes*                                                                                                             
                                                   **  **34 SNPs                                                       ≥8           47.58       48.51     48.49   ***0.00012***    *0.0094*
                                                      * SNCA*                                                                                                                     
                                                     rs17015888                                                        13           72.28       76.96     75.58   ***0.000013***   *0.023*
                                                      * GFAP*                                                                                                                     
                                                      rs3169733                                                        9.5          58.92       60.38     60.17      *0.042*        0.158
                                                      rs736866                                                                                                                         
                                                      * DRD2*                                                                                                                     
                                                  **  **rs4648317                                                       9           15.38       14.92     15.61       0.293         0.429
                                                    ** ***GRM3*                                                                                                                   
                                                     rs17160519                                                         9           35.13       37.38     35.55   ***0.000061***    0.309
                                                      rs6944937                                                                                                                        
                                                     rs17315854                                                                                                                        
                                                      rs4236502                                                                                                                        
                                                                                                                                                                                       
                                                    ** ***MBP*                                                                                                                    
   **  **rs470131   rs2282566   rs736421   rs1789094   rs9951586   rs1789103   rs4890912   rs9947485   rs1124941       8.5          47.23       48.01     48.31      *0.0443*       0.059
                                                    ** ***MOBP*                                                                                                                   
                                            **  **rs562545   rs2233204                                                 8.5          50.28       50.80     50.75       0.233         0.337
                                                   ** ***GNAI1*                                                                                                                   
             **  **rs4731111   rs6466884   rs17802148   rs10486920   rs2523189   rs2886611   rs2886609                  8           61.58       63.03     62.87     *0.006435*      0.072
                                                      * MOG*                                                                                                                      
                                      **  **rs3117292   rs2747442   rs3117294                                           8           48.78       46.44     46.08      0.020216       0.056
                                                    ** ***RXRG*                                                                                                                   
                                                 **  **rs10800098                                                       8           2.62         3.42     3.33      *0.024279*      0.126
                                                      * SYT1*                                                                                                                     
                               **  **rs1569033   rs1245819   rs1268463   rs10861755                                     8           41.56       42.48     44.25      0.11474       *0.0087*

Abbreviations: GRPS, Genetic Risk Prediction Score; SNCA, synuclein alpha; SNP, single-nucleotide length polymorphism. Italic, nominally significant; bold italic, survived Bonferroni correction.
